Corpus Intelligence IC Memo — BALLINGER MEMORIAL HOSPITAL 2026-04-26 15:42 UTC
IC Memo — BALLINGER MEMORIAL HOSPITAL
Investment Committee Memorandum | TX | 16 beds | Grade D | EBITDA uplift $1.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BALLINGER MEMORIAL HOSPITAL

CCN 451310 | RUNNELS, TX | 16 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

BALLINGER MEMORIAL HOSPITAL is a 16-bed community hospital in RUNNELS, TX with $17.2M in net patient revenue and a 6.5% operating margin. The hospital serves a payer mix of 61.8% Medicare, 0.0% Medicaid, and 38.2% commercial.

Thesis: Turnaround. Our ML models identify $1.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 6.5% to 13.9% (+736bps).

Net Revenue HCRIS$17.2M
Current EBITDA COMPUTED$1.1M
Operating Margin COMPUTED6.5%
Occupancy HCRIS23.8%
Revenue / Bed COMPUTED$1.1M
Net-to-Gross HCRIS50.7%
Distress Probability MLnan%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
171
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of 6.5% places it above the state median. Among 171 size-comparable peers (8-32 beds), the median margin is -16.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (8-32), prioritizing same-state peers. 171 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BALLINGER MEMORIAL HOSPITAL (Target)TX16$17.2M6.5%
CORYELL MEMORIAL HOSPITALTX25$305.9M-1.5%
METHODIST HOSPITAL FOR SURGERYTX32$178.4M22.8%
TEXAS SPINE AND JOINT HOSPITALTX20$147.3M30.3%
NORTH CENTRAL SURGICAL HOSPITATX24$143.6M32.0%
SCOTT AND WHITE HOSPITAL TAYLOTX25$139.7M-47.5%
BAYLOR SURGICAL HOSPITAL AT FOTX30$136.0M14.8%
BAYLOR ORTHOPEDIC AND SPINE HOTX24$133.8M39.8%
UVALDE MEMORIAL HOSPITALTX21$89.9M30.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$362K+210bp18mo
Cost to Collect4.5%2.5%$344K+200bp12mo
Denial Rate Reduction12.0%6.5%$341K+198bp12mo
A/R Days Reduction5200.0%3800.0%$210K+122bp9mo
Clean Claim Rate88.0%96.0%$11K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$362K
Cost to Collect
$344K
Denial Rate Reduction
$341K
A/R Days Reduction
$210K
Clean Claim Rate
$11K
Total EBITDA Uplift$1.3M
Current EBITDA$1.1M
+ RCM Uplift+$1.3M
Pro Forma EBITDA$2.4M
Current Margin6.5%
Pro Forma Margin13.9%
WC Released (1x)$661K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.7M$20.1M11.61x63.3%
Base (11x exit)10.0x11.0x$1.7M$22.7M13.09x67.3%
Bull Case9.0x11.0x$1.6M$27.4M17.59x77.4%
Bull (12x exit)9.0x12.0x$1.6M$30.4M19.48x81.1%
Bear Case11.0x10.0x$1.9M$13.2M6.93x47.3%
Bear (11x exit)11.0x11.0x$1.9M$15.1M7.95x51.4%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 61.8% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement
MediumLow occupancyAt 23.8%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 171 hospitals with 8-32 beds
  • Same-state prioritization (n=175)
  • Comp margins: P25=-46.1% / P50=-16.9% / P75=8.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.